About: New variant of human tissue plasminogen activator (TPA) with enhanced efficacy and lower incidence of bleeding compared with recombinant human TPA

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: New variant of human tissue plasminogen activator (TPA) with enhanced efficacy and lower incidence of bleeding compared with recombinant human TPA Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article published on 01 November 1995

Attributes	Values
rdf:type	Item
description	wetenschappelijk artikel (nl) наукова стаття, опублікована в листопаді 1995 (uk) im November 1995 veröffentlichter wissenschaftlicher Artikel (de) scientific article published on 01 November 1995 (en) artículu científicu espublizáu en payares de 1995 (ast)
publication date	wds:Q71807529-25371319-D8FA-4508-B74E-2AEF5FE57A8B
publication date	1995-11-01 00:00:00Z (xsd:dateTime)
language of work or name	wds:Q71807529-57639E9A-A456-4233-991C-FB6817A266FC
language of work or name	English
author name string	wds:Q71807529-2E917EEA-E116-4F64-8A09-B57D9E5BF724 wds:Q71807529-45BCB90A-DE9B-499F-B867-935C0685D5F4 wds:Q71807529-A056E5E9-2D18-4FAA-8264-B81ED402004B wds:Q71807529-DC188FED-8E5B-4482-8F2D-00F1C300DA0D wds:Q71807529-DC94241F-25A5-49C0-B1FE-3C55068EA47B wds:Q71807529-E7033BF0-CEAB-4F03-AF5D-BEF78C6E4E18 wds:Q71807529-EE97B651-B7AE-446D-B449-43ACBA338C18
author name string	C R Benedict G R Thomas R Pakala W F Bennett N F Paoni B A Keyt C J Refino
rdfs:label	New variant of human tissue plasminogen activator (nl) New variant of human tissue plasminogen activator (TPA) with enhanced efficacy and lower incidence of bleeding compared with recombinant human TPA (en)
skos:prefLabel	New variant of human tissue plasminogen activator (nl) New variant of human tissue plasminogen activator (TPA) with enhanced efficacy and lower incidence of bleeding compared with recombinant human TPA (en)
name	New variant of human tissue plasminogen activator (nl) New variant of human tissue plasminogen activator (TPA) with enhanced efficacy and lower incidence of bleeding compared with recombinant human TPA (en)
title	wds:Q71807529-69E734EC-83A3-47E4-B76F-4A4BBB4E6F54
title	New variant of human tissue plasminogen activator (TPA) with enhanced efficacy and lower incidence of bleeding compared with recombinant human TPA (en)
page(s)	wds:Q71807529-C9C86AC3-5CEC-4B3C-940A-0C5598605334
page(s)	3032-3040
instance of	wds:Q71807529-D94C8F4B-C5F4-4389-8A99-4A68FA2FF565
instance of	scholarly article
main subject	wds:Q71807529-BCE2DB14-C5FD-4EE2-B136-E8D1C49986A8
main subject	plasminogen
PubMed ID	wds:Q71807529-6116D665-EFA4-49A3-B676-C353D4D87283
PubMed ID	http://rdf.ncbi.nlm.nih.gov/pubchem/reference/7586274
PubMed ID	7586274
published in	wds:Q71807529-ACEC23C1-7900-4556-A212-FD04FF9F56F6
published in	Circulation
issue	wds:Q71807529-98A1F3FC-0604-488D-8CA6-3353F0B3BAD2
volume	wds:Q71807529-23EEA3EB-9572-40BC-AFDB-1757581D33EB
issue	10
volume	92
DOI	wds:Q71807529-1AC697EB-7704-448E-88DC-74CDD4620BDA
DOI	http://dx.doi.org/10.1161/01.CIR.92.10.3032
DOI	10.1161/01.CIR.92.10.3032
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q71807529
is cites work of	Absence of paradoxical thrombin activation by fibrin-specific thrombolytics in acute myocardial infarction: comparison of single-bolus tenecteplase and front-loaded alteplase Advances in the medical management of acute coronary syndromes Safety assessment of single-bolus administration of TNK tissue-plasminogen activator in acute myocardial infarction: the ASSENT-1 trial. The ASSENT-1 Investigators Fibrinogen-coated albumin microcapsules reduce bleeding in severely thrombocytopenic rabbits The Norwegian tenecteplase stroke trial (NOR-TEST): randomised controlled trial of tenecteplase vs. alteplase in acute ischaemic stroke Characterization of the glycosylation occupancy and the active site in the follow-on protein therapeutic: TNK-tissue plasminogen activator Optimizing the use of thrombolytics in ST-segment elevation myocardial infarction Development of the Nitrone‐Based Spin Trap Agent NXY‐059 to Treat Acute Ischemic Stroke Alteplase versus tenecteplase for thrombolysis after ischaemic stroke (ATTEST): a phase 2, randomised, open-label, blinded endpoint study. Prophylactic thrombolysis by thrombin-activated latent prourokinase targeted to PECAM-1 in the pulmonary vasculature Pharmacokinetics and pharmacodynamics of tenecteplase in fibrinolytic therapy of acute myocardial infarction. Molecular biology of plasminogen activators: what are the clinical implications of drug design? Identification of the unpaired cysteine status and complete mapping of the 17 disulfides of recombinant tissue plasminogen activator using LC-MS with electron transfer dissociation/collision induced dissociation Plasminogen activator inhibitor type-1 (part two): role for failure of thrombolytic therapy. PAI-1 resistance as a potential benefit for new fibrinolytic agents Inhibition of arterial thrombosis by a peptide ligand of the thrombin receptor Human complement receptor type 1-directed loading of tissue plasminogen activator on circulating erythrocytes for prophylactic fibrinolysis Drug delivery by red blood cells: vascular carriers designed by mother nature Postischemic intracarotid treatment with TNK-tPA reduces infarct volume and improves neurological deficits in embolic stroke in the unanesthetized rat. Prophylactic fibrinolysis through selective dissolution of nascent clots by tPA-carrying erythrocytes Targeting therapeutics across the blood brain barrier (BBB), prerequisite towards thrombolytic therapy for cerebrovascular disorders-an overview and advancements Tenecteplase versus alteplase for management of acute ischaemic stroke (NOR-TEST): a phase 3, randomised, open-label, blinded endpoint trial. Gene therapy to promote thromboresistance: local overexpression of tissue plasminogen activator to prevent arterial thrombosis in an in vivo rabbit model Thrombolysis of occluded peripheral arteries and veins with tenecteplase: a pilot study The Open Artery Hypothesis: Past, Present, and Future Thrombolytic therapy: a review of its use in acute myocardial infarction Tenecteplase versus Alteplase for the Management of Acute Ischemic Stroke in a Low-income Country-Nepal: Cost, Efficacy, and Safety. Safety and efficacy of tenecteplase in acute myocardial infarction Different doses of tenecteplase vs alteplase in thrombolysis therapy of acute ischemic stroke: evidence from randomized controlled trials Recanalization before Thrombectomy in Tenecteplase vs. Alteplase-Treated Drip-and-Ship Patients
is cites work of	wds:Q28193615-B0D6FD18-3CFC-4DF6-8935-7014D78E0E6E wds:Q33655204-7B45DF16-BB26-4939-98FF-DE2DE9F7702C wds:Q51379415-0A7C1AFD-AC70-4617-BE9E-5EA8C39478A0 wds:Q36445835-83ACB459-ED98-4550-8235-2C2BB0A589E2 wds:Q40769718-AF23F03A-1C04-4BB3-9737-039682B6DD64 wds:Q48304361-6E53BEA7-95B5-4D4C-9B70-C858AA7C79C0 wds:Q44661262-1C2ABDDA-6C28-403F-AA5F-ECA5E34A79AA wds:Q73621576-1445B600-95CC-42A2-8B69-AFB921C290B6 wds:Q37595489-4CAEFAE2-AEB1-4183-890C-2E93CB84D07E wds:Q41303102-9C9AE212-FAF8-4E2A-930B-D3EC518380E9 wds:Q74815558-24C5FC5A-E316-421A-BF74-9A790FF5AE98 wds:Q35552845-890FC2ED-A47A-4538-9059-EB3AEE43B275 wds:Q33504864-A250A2AA-47E4-4F8A-BA10-2838FE1DFB0B wds:Q34953097-122CA0F4-C5E0-433F-8FC9-F49506E96AF2 wds:Q38638909-F48FBC3A-B338-4C1C-855C-F077202C7ED1 wds:Q41321342-779C8A04-594D-4D99-89D1-8A1C427D084A wds:Q55008330-AEE24239-1EE5-4B88-B420-DBAB343EB007 wds:Q90257301-F0CA60BD-1BD5-4D75-95F1-8DDF5D437899 wds:Q39401174-742ED388-5814-44CD-8AA2-166335F6F660 wds:Q73128626-0BA22CCB-F2E2-4ADA-9A5E-5490A76EBE49

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 170 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software